SGEN US81181C1045

Report

Delayed Nasdaq - 06/11 04:00:01 pm
156.58	USD		-1.20%

06/07

SPRINGWORKS THERAPEUTICS : Seagen Working Together to Study Multiple Myeloma Combination Therapy

06/03

SEAGEN : Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting

06/02

SEAGEN : to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

06/07/2021	06/08/2021	06/09/2021	06/10/2021	06/11/2021	Date
154.01(c)	154.63(c)	155.59(c)	158.48(c)	156.58(c)	Last
778 089	532 548	958 776	612 598	481 320	Volume
+3.85%	+0.40%	+0.62%	+1.86%	-1.20%	Change

More quotes

Financials (USD)

Sales 2021	1 488 M - -
Net income 2021	-429 M - -
Net cash position 2021	2 665 M - -
P/E ratio 2021	-66,3x
Yield 2021	-

Sales 2022	2 236 M - -
Net income 2022	30,7 M - -
Net cash position 2022	2 348 M - -
P/E ratio 2022	1 154x
Yield 2022	-

Capitalization	28 416 M 28 416 M -
EV / Sales 2021	17,3x
EV / Sales 2022	11,7x
Nbr of Employees	2 092
Free-Float	99,3%

More Financials

Company

Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV...

Sector

Biotechnology & Medical Research

Calendar

07/29

Earnings Release

More about the company

Ratings of Seagen Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

All news about SEAGEN INC.

06/07	SPRINGWORKS THERAPEUTICS : Seagen Working Together to Study Multiple Myeloma Co..	MT
06/03	SEAGEN : Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in ..	BU
06/02	SEAGEN : to Present at the Goldman Sachs 42nd Annual Global Healthcare Conferen..	BU
05/20	ASTELLAS PHARMA : and Seagen Announce Updated Results from Two Trials of PADCEV..	AQ
05/20	SEZARY SYNDROME PIPELINE : Emerging Therapies and Key pharma players involved by..	AQ
05/19	SEAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
05/18	INSIDER TRENDS : Seagen Insider Receives Stock Award and Converts/Exercises Deri..	MT
05/18	Astellas to Present Data from Expanding Oncology Portfolio During the 2021 AS..	AQ
05/17	SEAGEN : Evercore ISI Initiates Coverage on Seagen With In-Line Rating, $153 Pr..	MT
05/13	INSIDER TRENDS : Insider Sale at Seagen Slowing 90-Days of Buying	MT
04/30	SEAGEN : Berenberg Bank Adjusts Seagen PT to $197 From $208, Maintains Buy Rati..	MT
04/30	SEAGEN : Oppenheimer Adjusts Seagen PT to $208 From $213, Maintains Outperform ..	MT
04/30	SEAGEN : Piper Sandler Adjusts Seagen's Price Target to $160 From $170, Maintai..	MT
04/30	SEAGEN : Credit Suisse Lowers Seagen's PT to $141 from $145 After In Line Q1 Re..	MT
04/30	SEAGEN : RBC Capital Adjusts Seagen PT to $148 From $169 Following Dissapointin..	MT

More news

News in other languages on SEAGEN INC.

2020	US-Konzern Merck & Co übernimmt Krebsforscher Velosbio
2020	10 Biotechs qui font parler d'elles
2020	Aktien New York Schluss: Übernahmen bescheren starken Wochenauftakt
2020	Aktien New York: Übernahme-Welle sorgt für einen starken Wochenauftakt
2020	DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 14.09.2020 - 15.15 Uhr

More news

Analyst Recommendations on SEAGEN INC.

05/17	SEAGEN : Evercore ISI Initiates Coverage on Seagen With In-Line Rating, $153 Pr..	MT
04/30	SEAGEN : Berenberg Bank Adjusts Seagen PT to $197 From $208, Maintains Buy Rati..	MT
04/30	SEAGEN : Oppenheimer Adjusts Seagen PT to $208 From $213, Maintains Outperform ..	MT

More recommendations

Provided by Scoopnest.com

Analysis

Wall Street closes broadly higher on deal news, vaccine hopes